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1. Introduction  
This article describes original work performed in our laboratory related to the 
characterization of kinase inhibitors developed to treat myeloid leukemia, as well as 
identified mechanisms that likely contribute to resistance to kinase inhibition. Specifically, 
we provide detailed overviews of the kinase inhibitors nilotinib, used in the treatment of 
chronic myeloid leukemia (CML) and midostaurin, which is currently under investigation in 
late stage clinical trials for the treatment of mutant FLT3-positive acute myeloid leukemia 
(AML). Presented as well is a description of studies investigating strategies that leukemic 
cells employ to escape killing through kinase inhibition, including alterations in the 
expression and composition of targeted proteins and chemoresistance conferred by the bone 
marrow microenvironment. We provide a general overview of kinase inhibitors in 
preclinical and clinical development for CML and AML, and also discuss the use of 
combination therapy as an approach to enhancing the efficacy of tyrosine kinase inhibition 
and reducing the incidence of residual disease. 
2. Development of BCR-ABL inhibitors and combination therapy studies 
geared toward overriding resistance to BCR-ABL inhibition 
Imatinib resistance: Introduction 
The development of resistance in leukemia patients to treatment with targeted tyrosine 
kinase inhibitors is a growing area of concern.  For instance, the ABL inhibitor imatinib 
(STI571) (Druker et al., 1996; Buchdunger et al., 2001), which also inhibits KIT and platelet-
derived growth factor receptor (PDGFR), has proven to be a highly effective, front line 
therapy for CML, a hematopoietic malignancy caused by the product of a reciprocal t(9;22) 
chromosomal translocation, BCR-ABL (Deininger et al., 2000). This targeted therapy has 
changed how newly diagnosed CML patients are treated and has substantially improved 
their prognosis. However, patients in the more advance phases of CML (namely, accelerated 
or blast crisis phase CML patients) often relapse due to drug resistance resulting from the 
emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase 
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
42
domain that reduce sensitivity towards imatinib (Gorre et al., 2001) or amplification of the 
target gene (Weisberg and Griffin, 2000).  
Imatinib resistance and disease relapse in some patients can also be due to BCR-ABL-
independent mechanisms, as exemplified by the small residual pool of BCR-ABL-positive 
quiescent leukemic stem cells existing in CML patients that have achieved complete 
responses after imatinib treatment. This inability of imatinib to completely eradicate 
quiescent leukaemic stem cells occurs despite the high expression of BCR-ABL mRNA and 
protein in these cells (Michor et al., 2005; Roeder et al., 2006; Copland et al., 2006), which 
suggests that these leukemic stem cells are not dependent on BCR-ABL for viability. 
Therefore, a population of BCR-ABL-positive, quiescent stem cells continues to exist after 
imatinib therapy even in patients who have achieved complete responses, and the 
insensitivity of these cells to imatinib is believed to contribute to relapse observed in some 
patients following termination of imatinib treatment. The existence of this quiescent cell 
population is important to consider when attempting development of effective therapies for 
overriding intrinsic kinase inhibitor resistance and resistance due to stromal-mediated 
mechanisms. Such novel treatment approaches must be able to eradicate this cell population 
if maximum clinical benefit and complete disease-free survival is to be achieved.  
Among strategies to override imatinib resistance are the direct targeting of the BCR-ABL 
protein and the targeting of mediators of signaling pathways downstream of BCR-ABL that 
are needed for transformation. Biorational drug design has led to the development of novel 
agents that overcome some forms of imatinib resistance, and impressive results obtained in 
clinical trials have led to rapid FDA approval of second generation compounds that are 
presently used to treat newly diagnosed CML patients. 
BCR-ABL point mutations as a mechanism of imatinib resistance 
Although early studies based on cell line models pointed toward BCR-ABL gene 
amplification and over-expression of BCR-ABL mRNA and protein as contributing to 
imatinib resistance (Weisberg and Griffin, 2000; Mahon et al., 2000; le Coutre et al., 2000), the 
most common mechanism of imatinib resistance was later discovered to be point mutations 
in the BCR-ABL gene that lead to changes in amino acids in the BCR-ABL protein catalytic 
domain. Of the mechanisms considered to be of major importance in the development of 
drug resistance, gene amplification accounts for approximately 10% of relapse in patients, 
whereas mutations in the kinase domain account for 40-90% of relapse in patients. Other 
important mechanisms include mutations or activation of other genes (i.e. Lyn) (Wu et al., 
2008) and the contribution of organic cation transporter 1 or other related drug pumps 
(Engler et al., 2010). Mechanisms of minor importance or uncertain significance include the 
influence of multidrug resistance 1 gene  (Gambacorti-Passerini et al., 2000) and alpha1 
acidic glycoprotein (Mahon et al., 2000).  
BCR-ABL point mutations, which diminish the binding of imatinib to its target, are often 
those that directly or indirectly impair the binding of imatinib to the BCR-ABL protein 
without compromising the function of the ABL tyrosine kinase domain. Point mutations 
that reduce imatinib binding through a direct mechanism are generally positioned around 
the imatinib binding site, and diminish imatinib binding through alterations in amino acid 
side chains or topographical changes that sterically hinder the binding of imatinib. Phe317 
and Thr315 are examples of this type of BCR-ABL point mutation (Cowan-Jacob et al., 2004).  
Point mutations that reduce imatinib binding through an indirect mechanism utilize the 
distinct binding mode of a drug to BCR-ABL. Generally, there are three primary kinase 
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inhibitor binding modes that represent main mechanisms for pharmacological inhibition of 
kinase activity (Liu and Gray et al., 2006): 
1. Kinase inhibitor directly competes with ATP in the ATP binding site. Inhibitors of this 
type are known as “Type I” and bind to the “Asp-Phe-Gly (DFG)-in” conformation (the 
“DFG” motif is highly conserved in protein kinases and sits near the beginning, or N-
terminus, of the activation loop) .   
2. Kinase inhibitor engages an adjacent allosteric binding site, typically accessible when 
the activation loop and/or alpha-c helix is folded away from the binding site, which 
leads to kinase inactivation. Inhibitors of this type are known as “Type II” and bind to 
the “DFG-out” conformation. 
3. Kinase inhibitor binds at sites distal from the ATP binding site. 
Imatinib, a “Type II” inhibitor, binds to the catalytically inactive conformation of the ABL 
kinase domain. BCR-ABL point mutations that destabilize the inactive conformations of the 
DFG motif diminish the binding capacity of imatinib, and therefore work through an 
indirect mechanism.  
Over fifty different BCR-ABL point mutations have been identified (Rourmiantsev et al., 
2002; Von Bubnoff et al., 2002; Shah et al., 2002; Hochhaus et al., 2002) and generally fall into 
different categorical regions that include the hinge region (which bridges the C- and N-
terminal lobes of the kinase domain to develop the ATP-binding cleft), A-loop, and P-loop 
(or “nucleotide-binding loop”). The position of the A-loop, which includes amino acids 381-
402, regulates ABL kinase activity. Mutations in the A-loop typically confer moderate 
resistance. In contrast, P-loop mutations, which occur at the binding site for phosphates of 
ATP, include amino acids 244-255 of ABL, are highly imatinib-resistant, and confer a worse 
prognosis than other mutations (Soverini et al., 2005). Point mutations in the ABL kinase 
domain that destabilize the inactive conformations of the P-loop increase the free energy of 
the imatinib-ABL drug-protein complex, and in effect diminish imatinib binding. Gly250, 
Tyr 253, and Glu255 in the P-loop are examples of mutations that reduce imatinib binding 
through an indirect mechanism.  
The vast majority of the BCR-ABL point mutations identified occur infrequently. Mutations 
such as those occurring at residues Thr315, Phe359, Met351, Gly250, Glu255, and Tyr253 
comprise up to 70% of all existing mutations. It is possible that extremely rare levels of BCR-
ABL point mutations pre-exist treatment with imatinib and increase in frequency during 
imatinib therapy (Roche-Lestienne et al., 2002; Hofmann et al., 2003). 
In addition to detection of BCR-ABL point mutations in patients, BCR-ABL point mutations 
characterized as conferring imatinib resistance have been identified through in vitro random 
mutagenesis of BCR-ABL (Shah et al., 2002; Hochhaus et al., 2002). Some identified 
mutations were found to exist distal to the kinase domain, including the Src homology 2 
(SH2) and SH3 domains and N-terminal cap region (Hochhaus et al., 2002; Azam et al., 2003; 
Pluk et al., 2002). 
The detection of a point mutation in the BCR-ABL kinase domain was first reported in 
imatinib-resistant CML patients: three out of nine patients were characterized by BCR-ABL 
gene amplification, while six out of nine patients were characterized by an isoleucine 
substitution in the Thr315 residue located at the periphery of the nucleotide-binding site of 
ABL (also referred to as the “gatekeeper position”) (Gorre et al., 2001).  The Thr315 residue, 
located in the hinge region, participates through a hydroxymethylene side chain in a critical 
H-bond interaction between imatinib and its protein target (Schindler et al., 2000; Manley et 
al., 2002; Nagar et al., 2002). Mutation of threonine to isoleucine confers resistance to 
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imatinib because of direct steric intrusion of the bulky isoleucine side chain, as well as loss 
of the hydrogen-bonding interaction in the ATP-cleft. An independent study of the crystal 
structure of an imatinib analog bound to ABL had shown Thr315 to be critical for the 
binding of imatinib to ABL, and the mutation of threonine to valine at this residue (T315V) 
was observed to confer imatinib resistance (Schindler et al., 2000; Corbin et al., 2002). 
Development of second generation BCR-ABL inhibitors designed to override imatinib resistance 
Nilotinib 
As an approach to overriding imatinib resistance, we characterized and developed the 
phenylaminopyrimidine-based Type II ATP competitive inhibitor, nilotinib (NVP- 
AMN107-NX; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-
3-pyridinyl)-2-pyrimidinyl]amino]benzamide), based on the crystal structures of inhibitors 
complexed with ABL (Cowan-Jacob et al., 2004). As with imatinib, another Type II ATP 
competitive inhibitor, part of nilotinib’s structure binds the ATP binding site, while part of 
its structure binds adjacent to the ATP binding site. Nilotinib was designed to fit into the 
ATP-binding site of BCR-ABL with higher affinity than imatinib, and demonstrates 
significantly higher potency than imatinib in inducing apoptosis of BCR-ABL-expressing 
cells (IC50<10 nM) by directly inhibiting ABL tyrosine kinase (Weisberg et al., 2005). 
Nilotinib also shows activity against a panel of imatinib-resistant BCR-ABL mutants, with 
the exception of T315I, and is effective in preventing the onset of leukemia in a BCR-ABL+ 
leukemic mouse model, and in prolonging the survival of mice harboring imatinib-resistant 
BCR-ABL-expressing cells (Weisberg et al., 2005; O'Hare et al., 2005). Crystallographic 
analysis of nilotinib complexed with ABL shows that, like imatinib, nilotinib binds to the 
inactive conformation of ABL. This suggests that the superior topographical fit to the ABL 
protein, as well as differences in the binding nature of nilotinib to ABL, contribute to the 
higher potency of nilotinib versus imatinib. 
Clinical trial results with nilotinib in imatinib-resistant patients were favorable (Kantarjian 
et al., 2006; le Coutre et al., 2006; Ottmann et al., 2006). A phase III randomized, open-label 
multicenter study was conducted as a direct comparison of imatinib and nilotinib in CML 
patients. Results showed nilotinib to be superior to imatinib in patients with newly 
diagnosed chronic phase CML (Saglio et al., 2010).  On October 29, 2007, the FDA granted 
accelerated approval to nilotinib for use in the treatment of chronic phase and accelerated 
phase Philadelphia chromosome positive (Ph+) CML in adult patients resistant or intolerant 
to prior therapy that included imatinib. On June 17, 2010, the FDA granted accelerated 
approval to nilotinib for treatment of adult patients with newly diagnosed Ph+ CML in 
chronic phase.  
Dasatinib 
Dasatinib (BMS-354825) is a second generation Type I ATP competitive inhibitor of BCR-
ABL that is both a potent ABL inhibitor and a potent Src family kinase inhibitor (Shah et al., 
2004; O'Hare et al., 2005; Burgess et al., 2005; Das et al, 2006; Melnick et al., 2006).  Over-
expression and activation of Src family kinases, such as LYN and HCK, have been shown to 
be associated with imatinib resistance (Donato et al., 2003), which suggests that the 
simultaneous targeting of BCR-ABL and Src family kinases may be effective in overriding 
resistance to imatinib. Unlike imatinib and nilotinib, which bind to the inactive 
conformation of BCR-ABL, dasatinib binds to the active conformation (Tokarski et al., 2006). 
Similar to nilotinib, dasatinib is effective against a number of imatinib-resistant BCR-ABL 
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point mutants, with the notable exception of the T315I gatekeeper mutant (Shah et al., 2004; 
O’Hare et al., 2005; Burgess et al., 2005).  
Dasatinib received accelerated approval by the FDA in June 2006 and the European 
Medicines Agency (EMEA) in November 2006 for treatment of adults in all phase of CML 
with resistance or intolerance to imatinib treatment. This approval was based on positive 
results in early (Phase I and II) clinical trials (Talpaz et al., 2006; Cortes et al., 2007). 
Dasatinib was also approved for treatment of drug-resistant Ph+ acute lymphoblastic 
leukemia (ALL) patients, in which a 190 kDa BCR-ABL protein is expressed resulting from 
an alternative breakpoint in the BCR gene. As with nilotinib, dasatinib has been granted 
FDA approval for therapy of newly diagnosed CML patients (Kantarjian et al, 2010). 
Other BCR-ABL inhibitors 
Dual ABL and Src inhibitors, bosutinib (SKI-606) (Puttini et al., 2006; Golas et al., 2003), 
which is a Type I ATP competitive inhibitor that only occupies the region normally 
occupied by ATP, and INNO-406 (first developed as NS-187) (Kimura et al., 2005), are active 
against a panel of imatinib-resistant BCR-ABL point mutants with the exception of the T315I 
gatekeeper mutant. AZD0530 is another dual ABL and Src inhibitor and Type I ATP 
competitive inhibitor that only weakly inhibits BCR-ABL (Lockton et al., 2005; Hennequin et 
al., 2006).   
Aurora kinase inhibitors, which work through inhibition of the Aurora family of 
serine/threonine kinases, members of which are important for mitotic progression, 
represent another class of second generation inhibitors of BCR-ABL. Examples include 
PHA-739358 (Nerviano Medical Sciences) (Fancelli et al., 2006), which has been tested in 
early clinical trials in patients that relapsed after treatment with imatinib. PHA-739358 is a 
Type I inhibitor that binds the ATP binding site directly. Another example of an Aurora 
kinase inhibitor is MK-0457 (first developed as VX-680), which inhibits the proliferation of 
cells expressing the T315I-BCR-ABL gatekeeper mutant at submicromolar concentrations 
(Carter et al., 2005). MK-0457 has shown activity in some patients harboring the T315I 
mutation (Giles et al., 2007). 
Non-ATP-competitive BCR-ABL inhibitors represent another class of second generation 
BCR-ABL inhibitors that work either via a non-ATP competitive allosteric mechanism or by 
prevention of substrate binding. Examples include ON012380, which shows potent activity 
against BCR-ABL-positive cells (Gumireddy et al., 2005). Compounds of this class make a 
covalent bond to the kinase and act as irreversible inhibitors. One complication is the fact 
that these compounds bind the substrate binding sites of multiple kinases, and therefore are 
very cytotoxic. Consequently, no clinical compound has been derived from this series. Non-
ATP competitive inhibitors are also exemplified by the GNF2 and GNF5 family of inhibitors, 
which bind to the myristate binding site of BCR-ABL and inhibit its activity by stabilizing a 
catalytically less competent conformation of the protein (Adrian et al., 2006; Zhang et al., 
2010). In addition, a type II inhibitor, GNF-7, has been shown to inhibit the T315I mutant in 
vitro and in vivo (Choi et al., 2010).  
As an approach to overriding imatinib resistance, we developed and characterized HG-7-85-
01, which is a Type II ATP competitive inhibitor that opens up a new chemical space in the 
field of kinase inhibitor development (Weisberg et al., 2010a). The structural inspiration for 
HG-7-85-01 is an amalgam of dasatinib and nilotinib, and is mostly utilization of the Type II 
nilotinib binding mode. Part of the structure of HG-7-85-01 binds to the ATP binding site, 
while the other part of its structure binds adjacent to the ATP binding site. In addition to 
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
46
inhibiting T315I-BCR-ABL in CML, HG-7-85-01 was observed to inhibit gatekeeper mutants 
of multiple kinases of therapeutic interest including T670I c-Kit and T674I-PDGFRalpha, 
which are clinically observed in gastrointestinal stromal tumor (GIST) and 
hypereosinophilic syndrome (HEL). Despite this broad profile with respect to ‘gatekeeper’ 
mutant kinases, HG-7-85-01 is not a promiscuous inhibitor, and no other inhibitor has been 
reported to possess this biological profile. Demonstration that this multi-gatekeeper mutant 
profile can be achieved is very important to the field because many pharmaceutical 
companies are reluctant to develop inhibitors for drug-resistant mutant kinases as they do 
not believe a sufficient number of patients are likely to benefit. The biological profile of HG-
7-85-01 demonstrates that a single compound could be developed that is capable of 
simultaneously targeting drug-resistant target kinases relevant across a range of 
malignancies. 
Progress is being made toward development of pan-BCR-ABL inhibitors that target all 
identified BCR-ABL point mutants, including T315I-BCR-ABL gatekeeper mutation (the so-
called “third generation” of BCR-ABL inhibitors). However, as the potential for emergence 
of new drug-resistant BCR-ABL point mutations still exists, benefit is likely to be gained 
from further development of BCR-ABL inhibitors displaying higher potency and distinct 
mutagenicity profiles, as well as therapeutic approaches involving administration of more 
than one BCR-ABL inhibitor or combined use of signal transduction inhibitors and BCR-
ABL inhibitors.  
Combination therapy as an approach to overriding resistance to BCR-ABL inhibition 
As it was anticipated that, similar to imatinib, resistance to nilotinib and dasatinib would 
likely also emerge due to arising BCR-ABL point mutations in CML and Ph+ ALL, 
mutagenesis screens were performed to identify nilotinib- and dasatinib-resistant BCR-ABL 
point mutations and showed overlapping but distinct mutagenicity profiles (Von Bubnoff et 
al., 2006; Bradeen et al., 2006; Ray et al., 2007). There has been substantial interest in testing 
the notion that simultaneous or sequential administration of more than one ABL inhibitor 
might delay the onset of emergence of drug-resistant BCR-ABL point mutations. For 
instance, we have shown beneficial paired combinations of imatinib and nilotinib against 
imatinib-resistant CML (Weisberg et al., 2007a). Specifically, we demonstrate the synergistic 
interaction between nilotinib and imatinib against both non-mutated BCR-ABL and 
imatinib-resistant BCR-ABL point mutants. It has been suggested that the differential uptake 
mechanisms for imatinib and nilotinib may contribute to the observed synergy between the 
two agents (White et al., 2006). Alternatively, synergy may be explained by the ability of 
imatinib to increase the intracellular uptake and retention of nilotinib (and therefore its 
overall concentration), possibly through imatinib inhibition of ABCB1-mediated efflux of 
nilotinib (White et al., 2007). The demonstrated synergy between imatinib and nilotinib 
complements other published reports showing synergistic interaction between imatinib and 
the dual Src/Abl inhibitors, dasatinib and AP23848 (O’Hare et al., 2005), as well as 
synergistic interactions between imatinib and a panel of standard chemotherapeutic agents 
(Liu et al., 2002). In addition, combinations of dasatinib and imatinib have proven to be 
effective in diminishing the frequency of occurrence of drug-resistant BCR-ABL mutants, 
with the exception of T315I (Shah et al., 2004; Burgess et al., 2005; Bradeen et al., 2006; 
Talpaz et al., 2006). As improvement of disease-free survival could potentially be achieved 
from combination therapy involving inhibitors from the same or diverse structural classes, 
these studies could serve as a guide for further clinical investigation. 
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Since clonal resistance could potentially be overcome by combining two agents with 
different resistance profiles, we investigated the ability of HG-7-85-01 to positively combine 
with GNF-5, which is unable to potently inhibit T315I as a single agent (Zhang et al., 2010; 
Weisberg et al., 2010c). We demonstrated that combinations of HG-7-85-01 with GNF-5 have 
at least additive effects against both non-mutated BCR-ABL and BCR-ABL T315I in vitro and 
in vivo (Weisberg et al., 2010c).  GNF-5 was also shown to enhance the activity of nilotinib 
against both non-mutated BCR-ABL and T315I-BCR-ABL in vitro and in vivo (Zhang et al., 
2010).  
An important characteristic of leukemia that confers survival advantages is the common 
deregulation of one or more of the three signaling pathways: PI3K/PTEN/Akt/mTOR, 
RAS/Raf/MEK/ERK, and Jak/STAT, each frequently activated by mutations in upstream 
genes.  The redundancy and simultaneous/cross-activation between the three pathways 
warrants consideration of the use of a multi-targeted therapeutic strategy, or the use of more 
than one type of signaling inhibitor. We have shown that the dual PI3K/PDK-1 inhibitor, 
BAG956, has the ability to enhance the inhibitory effects of imatinib and nilotinib, 
respectively, to effectively kill BCR-ABL-expressing cells both in vitro and in vivo (Weisberg 
et al., 2008a). Similarly, enhanced apoptosis of BCR-ABL-positive cells has been found to 
result from treatment with a STAT5 inhibitor and imatinib or nilotinib (Nelson et al., 2011). 
In addition, inhibitors of MAPK and PI3K/Akt signaling have been implicated in up-
regulation of proapoptotic BIM expression (Strasser et al., 2005). This is of potential 
importance with respect to imatinib resistance, as the proapoptotic BH3 domain-only 
protein, BIM, as well as proapoptotic BAD, mediate imatinib-induced apoptosis (Kuroda et 
al., 2006). Of relevance, the BH3 mimetic, ABT-737, overrides imatinib resistance due to loss 
of BIM and BAD (Kuroda et al., 2006). Inhibition of PI3K/Akt signaling also may be of 
potential benefit insofar as stromal-mediated chemoresistance is concerned, as Akt has been 
shown to be involved in leukemic cell survival in the bone marrow microenvironment (Tabe 
et al., 2007).  
3. Development of inhibitors of FLT3, and combination therapy studies 
geared toward overriding resistance to FLT3 inhibition 
Mutant FLT3 as a therapeutic target for AML 
The hematological malignancy, AML, is generally characterized by a block in cellular 
differentiation at different stages and aberrant proliferation of myeloid precursor cells. Early 
models have indicated that two types of mutations are responsible for the development of 
AML: One type of mutation is responsible for blocking terminal differentiation and the 
other type of mutation is responsible for promotion of growth and viability. However, full 
genome sequencing results suggest that up to 20 different mutations initiate AML, and 
disease development is thus likely more complicated than what the two mutation model 
proposes.  
Approximately 30% of AML patients, as well as a portion of ALL patients,  express a 
mutated form of the class III receptor tyrosine kinase, FLT3 (Fms-Like Tyrosine kinase-3; 
STK-1, human Stem Cell Tyrosine Kinase-1; FLK-2, Fetal Liver Kinase-2) (Stirewalt and 
Radich, 2003). The existence of a FLT3 mutation generally translates into a poorer prognosis 
in terms of overall survival and disease-free survival (Mattison et al., 2007). The fact that 
FLT3 mutations are only found in a portion of AML cells suggests that FLT3 mutations may 
be involved in promotion of disease rather than initiation of disease. 
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The most prevalent form of constitutively activated FLT3, found in approximately 20-25% of 
AML patients (although in less than 5% of myelodysplastic syndrome patients), occurs as 
internal tandem duplications (ITDs) that are located within the juxtamembrane domain 
(Nakao et al., 1996; Horiike et al., 1997; Kiyoi et al., 1998; Kondo et al., 1999; Rombouts et al., 
2000). This mutation has been shown to cause a rapidly lethal myeloproliferative disorder in 
mice in the absence of a block in differentiation, suggesting that its main role may be to 
cause hyper-proliferation of primitive myeloid cells (Kelly et al., 2002a). Mutant FLT3 is 
believed to interact with additional oncogenes that block differentiation, such as 
AML1/ETO (t(8;21)) PML/RARalpha (t(15;17).) to cause full leukemia development. 
Occurring in approximately 7% of AML cases are gain-of-function FLT3 kinase domain 
point mutations, frequently at position 835 (Yamamoto et al., 2001). Also identified have 
been other kinase domain point mutations, including Y842C (Kindler et al., 2005) and N841I 
(Jiang et al., 2004). An activating point mutation with comparatively weaker transforming 
potential has also been discovered in a stretch of the FLT3 juxtamembrane domain (Reindl et 
al., 2006). 
Inhibitors of mutant FLT3 
There are several FLT3 inhibitors presently in clinical trials, and a number of novel agents 
under preclinical investigation. Unfortunately, the FLT3 inhibitors tested thus far clinically 
induce only partial and transient responses in patients- at best- when used as single agents.  
We identified and developed a small molecule inhibitor, the N-indolo-carbazole 
midostaurin (PKC412; N-benzoylstaurosporin), (Weisberg et al., 2002), a broad-spectrum 
first generation inhibitor that targets constitutively activated mutant FLT3. Other targets of 
midostaurin include (PDGFRbeta), c-KIT and c-FMS (Weisberg et al., 2002).  Midostaurin 
showed high potency against mutant FLT3 as a target in vitro, and progressive leukemia was 
prevented in mice transplanted with marrow transduced with a FLT3-ITD-expressing 
retrovirus (Weisberg et al., 2002).  
In early clinical trials, midostaurin administered in sequential and simultaneous 
combinations with standard chemotherapeutic agents such as daunorubicin and cytarabine 
induction and high-dose cytarabine consolidation yielded clinical responses with transient 
and/or reversible side effects (Stone et al., 2004). Midostaurin is one of several FLT3 
inhibitors presently undergoing clinical testing, and it is currently under investigation in 
late stage clinical trials for AML. 
We have demonstrated the activity of midostaurin against imatinib-resistant GIST 
(Weisberg et al., 2006). Specifically, we demonstrated the potent activity of midostaurin 
against cells expressing two PDGFRalpha mutants associated GIST: the V561D 
juxtamembrane domain mutation and the less imatinib-sensitive D842V kinase domain 
mutation. We also demonstrated the ability of nilotinib to positively combine with either 
imatinib or midostaurin against cells expressing the D842V-PDGFRalpha mutant. Findings 
reported introduce midostaurin as a potential treatment option for mutant PDGFRalpha-
positive GIST and warrant its clinical testing for this disease target. 
Additional multi-targeted inhibitors, such as dasatinib and the biaryl urea compound and 
first-generation inhibitor, sorafenib (BAY 43-9006), have been shown to have activity against 
mutant FLT3 and are under clinical investigation for AML (Auclair et al., 2007; Kancha et al., 
2007; Lierman et al., 2007; Zhang et al., 2008; Metzelder et al., 2009; Guerrouahen et al., 
2010). Other FLT3 inhibitors that have been clinically investigated and which elicited 
transient responses in early phase trials include the indolocarbazole alkaloid and first-
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generation inhibitor, CEP-701 (lestaurtinib) (Levis et al., 2002; Smith et al., 2004; Knapper et 
al., 2006), KW-2449 (Pratz and Levis, 2008; Pratz et al., 2009; Shiotsu et al., 2009), 3-
substituted indolinones SU5416 (Semaxanib) and SU5614 (Yee et al., 2002; Fielder et al., 
2003; Giles et al., 2003; O’Farrell et al., 2004), the indolinone derivative and first-generation 
inhibitor, SU11248 (SU011248, sunitinib) (Fielder et al., 2005; Kancha et al., 2007; O’Farrell et 
al., 2003a,b), and the piperazinyl quinazoline and first-generation inhibitor, MLN518 
(tandutinib; CT53518) (Kelly et al., 2002b; Cheng and Paz, 2008). Among FLT3 inhibitors in 
early development are the N-(4-(3-amino-1H-indazol-4yl)phenyl-N1(2-fluoro-5-
methylphenyl) urea ABT-869 (Albert et al., 2006; Shankar et al., 2007; Zhou et al., 2008), the 
benzimidalzole-quinoline CHIR-258 (TKI258) (Lopes de Menezes et al., 2005), the 
hydroxystyryl-acrylonitrile LS104 (Kasper et al., 2008) and AP24534 (Gozgit et al., 2011).  
AC220 (Chao et al., 2009; Zarrinkar et al., 2009) is a second-generation FLT3 inhibitor that 
exhibits significantly higher potency and selectivity than first-generation inhibitors, and is 
under clinical investigation for mutant FLT3-expressing AML and wild-type FLT3-
harboring AML. A study by Pratz and colleagues suggested, however, that the potency and 
selectivity of agents targeting mutant FLT3 may not, in fact, be the best predictor of clinical 
efficacy (Pratz et al., 2010). In their study, AC220 was found to be the most potent inhibitor 
of several common FLT3 inhibitors tested (including lestaurtinib, midostaurin, sorafenib, 
and sunitinib) and had the highest index of selectivity. However, lestaurtinib- which had the 
lowest index of selectivity- was found to be the most effective when tested against FLT3-
ITD-positive patient samples. Results shown in this study suggested that inhibition of FLT3 
autophosphorylation in a FLT3-ITD specimen does not always induce death.  For example, a 
side-by-side comparison of AC220 and lestaurtinib showed that while both compounds 
fully inhibited FLT3 autophosphorylation and suppressed downstream STAT5 activation in 
one patient sample, only lestaurtinib induced apoptosis. Relapsed AML samples were 
observed to be more sensitive to FLT3 inhibition than diagnostic AML, suggesting that some 
FLT3-ITD AML (i.e. diagnostic) may not be addicted to FLT3 signaling. This study 
suggested that more selective inhibitors, like AC220 may be less effective in the diagnostic 
setting while less selective inhibitors- like lestaurtinib or midostaurin- may be more effective 
at diagnosis.  
Resistance to FLT3 inhibition 
Thus far, none of the FLT3 inhibitors under clinical investigation has elicited a sustained 
clinical response when used as a single agent. As an example, a phase I clinical trial for KW-
2449 showed that FLT3 inhibition in patients occurred only transiently to less than 20% of 
baseline levels (Pratz et al., 2009). It has been suggested that partial and transient FLT3 
inhibition such as this applies to other FLT3 inhibitors in clinical development and may be 
responsible for their limited efficacy (Chu and Small, 2009).  
One putative resistance mechanism related to FLT3 inhibition is dysregulation of signaling 
molecules, such as those associated with the PI3K/Akt and Ras/MEK/MAPK pathways 
(Piloto et al., 2007). Also implicated in drug resistance are aberrant STAT signaling (Zhou et 
al., 2009), the aberrant expression of the STAT5 target gene, PIM (Kim et al., 2005; Kim et al., 
2006), and high levels of phosphoprotein expression of the forkhead transcription factor, 
FOXO3A (Kornblau et al., 2010). Additional mechanisms include up-regulation of anti-
apoptotic proteins (Kohl et al., 2007; Brietenbuecher et al., 2009; Stolzel et al., 2010), up-
regulation of inhibitors of apoptosis proteins, and elevated FLT3 ligand levels (Zhou et al., 
2009). The concentration of FLT3 ligand has been observed to be significantly higher in 
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patients treated with chemotherapy or radiotherapy (Lyman et al., 1995; Wodnar-Filipowicz 
et al., 1996; Zwierzina et al., 1999; Bojko et al., 2002), and this is predicted to impede the 
action of FLT3 inhibitors administered after chemotherapy.  
Another possible resistance mechanism is cytoprotection conferred by the bone marrow 
microenvironment. Indeed, FLT3 inhibition was found to actually enhance the survival of 
CD34+CD38-CD123+ leukemic stem cells and progenitor cells in a “niche-like” in vitro 
microenvironment that was comprised of factors including IL-6, IL-3, stem cell factor (SCF), 
and immobilized fibronectin (Mony et al., 2008).  Small molecule CXCR4 inhibitors may be 
effective in enhancing kinase inhibitor-induced apoptosis of stromal-protected leukemic 
cells, implicating a causal relationship between the chemokine receptor CXCR4 and stroma-
derived factor 1alpha (SDF-1a) interaction and drug-resistant leukemia (Zeng et al., 2006).  
Pre-existing or acquired point mutations in the FLT3 kinase domain that interfere with drug 
binding may also contribute to drug resistance in patients (Cools et al., 2004; Heidel et al., 
2006). 
Point mutations in the FLT3 receptor are generally analogous to point mutations in BCR-
ABL, the most prevalent mechanism of resistance to imatinib. However, there is little 
evidence for the existence of overlapping resistance profiles for FLT3 inhibitors, such as 
those demonstrated for imatinib, dasatinib, and nilotinib with respect to the T315I 
gatekeeper mutation (Von Bubnoff et al., 2006; Bradeen et al., 2006; Ray et al., 2007). Instead, 
non-overlapping mechanisms of resistance between PKC412, sorafenib, and SU5614 were 
found in a screening assay designed to study drug resistance profiles (Von Bubnoff et al., 
2009). For example, SU5614 resistance was characterized predominantly as mutations in the 
D835 residue, while sorafenib resistance was characterized by unique mutations such as 
F691L and point mutations in the Y842 residue (Von Bubnoff et al., 2009). Another study 
confirmed the involvement of acquired mutations, D835N and Y842H, in resistance to 
SU5614 (Bagrintseva et al., 2004). In contrast, PKC412 resistance was characterized by 
mutations in the N676 residue, which was previously identified and characterized in a 
PKC412-resistant AML patient as the sole determinant of drug resistance (Heidel et al., 
2006).  
In addition to non-overlapping mutagenicity profiles between existing FLT3 inhibitors, each 
shows variable activity toward different mutations, for example activation loop mutants 
versus ITD mutations. As an example, sunitinib inhibits ITD and activation loop mutants 
with equal potency, whereas sorafenib is less efficacious toward activation loop mutants 
than ITD (Kancha et al., 2007). PKC412 shows comparable activity against different FLT3 
activation loop mutants, whereas MLN518 shows variable activity (Clark et al., 2004; Barry 
et al., 2007). 
Combination therapy as an approach to treating mutant FLT3-positive disease 
As responses of patients to FLT3 inhibition is generally only partial and transient, there is a 
need for development of novel agents that can either be used effectively alone or combined 
with FLT3 inhibitors to suppress disease progression and prolong lifespan. FLT3 inhibitors 
have been tested in combination with standard chemotherapy agents as an approach to 
assessing the overall efficacy of combined therapies. For example, SU11248, combined with 
cytarabine or daunorubicin, exhibited additive-to-synergistic inhibitory effects on cells 
expressing mutant FLT3 (Yee et al., 2004). Similarly, CEP-701 showed synergy when 
combined with etoposide, mitoxantrone, daunorubicin, and cytarabine (Levis et al., 2004). 
PKC412 demonstrated synergy when combined with vincristine, 4-hydroperoxy-
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cyclophosphamide, etoposide, mitoxantrone, cytarabine, doxorubicin, and idarubicin 
(Mollgard et al., 2008; Furukawa et al., 2007). The sequence of administration of FLT3 
inhibitors and standard chemotherapy appears to often, depending on the FLT3 inhibitor, be 
sequence-dependent, resulting in antagonism when the FLT3 inhibitor is administered prior 
to chemotherapy and resulting in synergy when the FLT3 inhibitor is administered after 
chemotherapy (Pratz and Levis, 2008).  
One strategy geared toward overriding resistance to FLT3 inhibition includes the combined 
use of more than one FLT3 inhibitor, providing their interaction with the FLT3 protein target 
or FLT3 signaling pathway components is distinct enough for the two inhibitors to 
synergize. We demonstrated the potent and selective activity of the novel type II ATP 
competitive inhibitors, HG-7-85-01 and HG-7-86-01, against mutant FLT3, as well as their 
ability to synergize well with standard chemotherapeutic agents or midostaurin (Weisberg 
et al., 2010b). The ability of HG-7-85-01 and HG-7-86-01 to inhibit mutant FLT3, in addition 
to a number of gatekeeper mutants of multiple kinases of therapeutic interest, highlights 
their unique versatility and potential widespread clinical usefulness.  Other potent FLT3 
inhibitors, such as NVP-AST487, have the ability to effectively combine with midostaurin to 
kill drug-sensitive and insensitive mutant FLT3-expressing cells (Weisberg et al., 2008b). The 
ability of two targeted FLT3 inhibitors to synergize may translate into clinical benefit in 
terms of reducing toxicity, as clinical responses achieved with late-stage FLT3 inhibitors like 
midostaurin and CEP-701 depend on combined administration with standard 
chemotherapeutic agents. 
Alternatively, FLT3 inhibitors can be combined with small molecule inhibitors that interact 
with key mediators of major signaling pathways that play a significant role in AML. Cross-
talk between the three main pathways activated by mutant FLT3 (RAS/Raf/MEK/ERK, 
Jak/STAT, and PI3K/PTEN/Akt/mTOR) warrants the development of multi-targeted 
approaches for treatment of mutant FLT3-positive AML  (Brandts et al., 2005; Recher et al., 
2005; Kornblau et al., 2006; Rocnik et al., 2006; Al Shaer et al., 2008). We have shown that 
signaling pathway inhibitors, such as the dual PI3K/PDK-1 inhibitor, BAG956, can 
positively combine with midostaurin against mutant FLT3-positive cells (Weisberg et al., 
2008a). Of relevance, PKC412 and the mTOR inhibitor, rapamycin, synergize against 
PKC412-sensitive and –resistant mutant FLT3-expressing cells (Mohi et al., 2004). The 
rapamycin derivative, RAD001, enhances the anti-leukemic effects of sunitinib (Ikezoe et al., 
2006), as does the MEK1/2 kinase inhibitor, AZD6244 (ARRY-142886) (Nishioka et al., 
2008b). Other agents effective in killing mutant FLT3-expressing cells are heat shock protein 
90 (Hsp90) inhibitors and histone deacetylase inhibitors, which disrupt the major signaling 
pathways (Al Shaer et al., 2008; Nishioka et al., 2008a), and drugs that inhibit farnesyl-
transferase (Mollgard et al., 2008). 
4. Characterization of underlying mechanisms of stroma-mediated 
chemoresistance to tyrosine kinase inhibition  
In addition to identifying and developing potent kinase inhibitors representative of novel 
and unique structural classes with the ability to override drug resistance due to changes in 
the target protein, there is a push toward gaining a better understanding of the mechanisms 
underlying drug resistance in CML and AML as they relate to the leukemic cell 
microenvironment.  Bone marrow is comprised of hematopoietic and stromal cells, in 
addition to other factors including extracellular matrix and blood vessels; growth factors 
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and cell:cell interactions (Charbord et al. 1996). Bone marrow stroma and factors derived 
from stroma have been suggested to play a role in the long-term survival and proliferation 
of normal and leukemia cells (Ashley et al., 1994; Bradstock et al., 1996; Rafii et al., 1997; 
Lagneaux et al., 1998, Lagneaux et al., 1999; Konopleva et al., 2002; Litwin et al., 2002). 
Specifically, bone marrow stroma provides signals, such as granulocyte colony-stimulating 
factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and  terminal 
differentiation of hematopoietic stem cells or mediate/support their proliferation (Verfaillie 
et al., 1993; Liesveld et al., 1996; Harrison et al., 1997; Breems et al., 1997; O’Prey et al., 1998; 
Leslie et al., 1998; Shih et al., 1999). SSpenic stroma, as well, has been implicated in enhanced 
survival of both normal and leukemic cells (Shaked et al., 2005; Despars and O’Neill, 2006). 
Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blood of 
patients responds well, bone marrow responds less well. It appears possible that small 
numbers of leukemic CD34+ cells can persist in the marrow microenvironment of leukemia 
patients after years of therapy with kinase inhibitors. Stromal cells have been implicated, as 
they provide viability signals to leukemic cells that protect them from inhibitor effects. 
Indeed, the quantity of leukemic stem cells that rely on stroma to survive is predictive of 
disease outcome (Kumagai et al., 1996).   
We revealed highest tumor burden and residual disease to occur in vivo in stroma-associated 
tissues in imatinib/nilotinib-treated NCr nude mice, suggesting that significant reservoirs 
for tumor growth appear to be tissues that are able to support normal hematopoietic and 
malignant stem cell development (Weisberg et al., 2008c). These studies, which showed a 
pattern of leukemia distribution consistent with what is observed in imatinib- and nilotinib-
treated chronic myeloid leukemia patients, were followed by a more in-depth analysis of 
stroma-leukemia cell interactions that lead to protection of leukemia cells from nilotinib-
induced cytotoxicity. For the latter, we used the human BCR-ABL-positive cell line, KU812F, 
and the human bone marrow stroma cell line, HS-5, to more closely approximate the bone 
marrow-associated cytoprotection observed in drug-treated leukemia patients. Partial 
stromal-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment 
involved the cooperative interaction of members of a select panel of stromal-secreted 
viability factors, including IL-6 and GM-CSF (Weisberg et al., 2008c). Similar results were 
observed with mutant FLT3-positive leukemia cells treated with midostaurin in the presence 
of HS-5-stromal-conditioned media versus the same panel of stromal-secreted viability 
factors (Weisberg et al., 2009).  
5. Potentiation of anti-leukemic effects of tyrosine kinase inhibitors by IAP 
inhibition: Implications for use of IAP inhibition to prevent or reduce residual 
disease following tyrosine kinase inhibition  
Deregulated signaling molecules associated with viability/apoptotic signaling represent 
attractive targets for therapeutic intervention, and several strategies have emerged that may 
be effective in preventing drug resistance due to this.  One approach involves combining 
targeted inhibitors with small molecule inhibitors of key components of major signaling 
pathways affecting the viability/expansion of leukemic cells. Accordingly, we have 
developed effective inhibitors of the inhibitor of apoptosis (IAP) family of proteins (Liu et 
al., 2000; Wu et al., 2000), such as LBW242 (Weisberg et al., 2007b), and its structural analog, 
LCL161, which bind to and inhibit multiple IAPs (i.e. XIAP, c-IAP) to enhance the activity of 
different proapoptotic signaling pathways. We have demonstrated the ability of LBW242 to 
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synergize with midostaurin in vivo against progressive mutant FLT3-positive leukemia and 
to override stromal-mediated chemoresistance in vitro (Weisberg et al., 2007b).   
Clinical trial data with midostaurin show that while good responses are achievable in 
mutant FLT3-positive AML patient peripheral blood, patient bone marrow responses are 
more modest. This suggests that stromal cells provide viability signals to AML cells that 
protect the cells from the effects of the selective inhibitor being used. We investigated the 
responsiveness of Ba/F3-FLT3-ITD cells cultured in the presence and absence of WEHI 
(used as a source of IL-3) to the cytotoxic effects of midostaurin, and we found that the 
presence of IL-3 completely protected cells from midostaurin-inhibition of cellular 
proliferation (Weisberg et al., 2007b). In contrast to midostaurin, the IAP inhibitor, LBW242, 
inhibited Ba/F3-FLT3-ITD proliferation in both the absence and the presence of IL-3 
(Weisberg et al., 2007b). Interestingly, LBW242 plus midostaurin inhibited the growth of 
Ba/F3-FLT3-ITD cells cultured in the presence of IL-3 to a greater extent than either agent 
alone; this inhibition was similar to that achieved with co-administration of both agents in 
the absence of IL-3, suggesting that an IAP inhibitor is able to enhance the effects of a FLT3 
inhibitor and override chemoresistance due to provision of viability signals (Weisberg et al., 
2007b).  
In an attempt to more closely model putative stromal-AML cell interactions and stromal-
mediated viability signaling effects on the cytotoxic effects of midostaurin, we tested the 
human stroma cell line, HS-5, in combination with the mutant FLT3 AML line, MOLM-13-luc+ 
(luciferase was used to specifically quantify only the leukemia component in the assay using 
light emission). A confluent layer of HS-5 stromal cells enhanced the growth of MOLM13-luc+ 
cells and was partially protective against the inhibitory effects of midostaurin (Weisberg et al., 
2007b). LBW242 enhanced the cytotoxic effects of midostaurin against MOLM13-luc+ cells in 
the presence of HS-5 human stromal cells, supporting the notion that stromal-mediated 
viability signals may contribute to chemoresistance to FLT3 inhibitors  
(such as midostaurin) observed in marrow, as well as the idea that such resistance may be 
overcome by inclusion of IAP inhibitor treatment (Weisberg et al., 2007b). 
We have also shown the ability of LCL161 to significantly delay disease recurrence in mice 
injected with BCR-ABL-expressing cells and treated for several weeks with a moderate dose 
of nilotinib (Weisberg et al., 2010d).  Specifically, using in vitro models of intrinsic drug 
resistance and stromal-mediated chemoresistance, as well as functional mouse models of 
progressive and residual disease, we showed the ability of the novel IAP inhibitor, LCL161, 
to enhance the cytotoxic effects of tyrosine kinase inhibitors against leukemic disease. 
Importantly, we observed LCL161 to synergize in vivo with nilotinib to reduce leukemia 
burden significantly below the baseline level suppression exhibited by a moderate-to-high 
dose of nilotinib. Our results support the idea of using IAP inhibitors in conjunction with 
targeted tyrosine kinase inhibition to suppress or eradicate progressive and drug-resistant 
or residual disease. Phase I studies in advanced solid tumors are currently ongoing, and 
LCL161 is being considered for testing in clinical trials for leukemia. 
6. Conclusion 
Elucidation of mechanisms of resistance to tyrosine kinase inhibition is critical for the 
optimization of existing therapies and prolongation of patient survival via delaying or 
eradicating the recurrence of disease. For CML, the discovery and characterization of BCR-
ABL point mutations in the kinase target of a number of inhibitors in clinical use has been a 
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tremendous step forward in understanding an important underlying mechanism of drug 
resistance. While second generation BCR-ABL inhibitors, such as nilotinib and dasatinib, 
have proven to be highly effective in the clinic and override imatinib resistance to an extent, 
the existence of highly imatinib-resistant mutants, such as the T315I gatekeeper mutant, is a 
limiting factor. Even for third generation BCR-ABL inhibitors that are able to override T315I, 
the potential exists for the evolution of novel drug-resistant point mutations that impede the 
binding of drug to its target. Thus, there continues to be a need for development of BCR-
ABL inhibitors with high potency and unique mutagenicity profiles, as well as a continued 
need for combination therapy approaches to overriding drug resistance.  
For mutant FLT3-positive AML, due to the only transient and partial effects observed 
clinically with FLT3 inhibitors in late-stage development, there is an urgent need for the 
development of new treatment approaches that could potentially lead to improved clinical 
effectiveness. As with CML, the key to improved patient responsiveness may lie in 
continued development of compounds conferring a higher degree of potency, as well as 
novel combination therapy strategies.  
For both CML and mutant FLT3-positive AML, elucidation of mechanisms of resistance that 
are associated with leukemic cell survival, such as stromal-mediated chemoresistance and 
up-regulation of viability signaling molecules, warrants the investigation of single agent 
activity of pro-apoptotic agents. It also warrants the development of treatment approaches 
that rely on administration of kinase inhibitors combined with other agents targeting 
components of leukemia:stromal cell interactions and stromal-derived viability factors.  
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